On June 10, the CDE official website showed that the Category 1 new drug HS-10568 Injection has been submitted for marketing approval. Based on public information and clinical trial progress, the Insight database speculates that the submitted indication is for…
On June 10 local time, Sanofi announced the termination of the Phase III MOBILIZE study (NCT06290128) of Riliprubart in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP). Riliprubart (SAR445088, BIVV020) is a humanized IgG4 monoclonal antibody that selectively inhibits activated…
On June 10, Laekna Therapeutics issued an announcement stating that it has entered into an exclusive license agreement with Vasque Bio, Inc. Under the terms and conditions of the license agreement, Laekna has granted Vasque Bio an exclusive worldwide license…
At the 2026 ASCO Annual Meeting, Zelgen Pharmaceuticals announced for the first time the Phase II clinical data of ZG005, a PD-1/TIGIT bispecific antibody, in combination with bevacizumab as a first-line treatment for advanced hepatocellular carcinoma (HCC). Compared with the…
On June 9, the NMPA official website showed that a new indication for Tian Guangshi’s MIL62 (generic name: Obinutuzumab β Injection) has been approved for marketing, for the treatment of primary membranous nephropathy (PMN), making it the world’s first targeted…
On June 9, the NMPA official website showed that a new indication for Henlius’ PD-1 monoclonal antibody Serplulimab has been approved for marketing — in combination with oxaliplatin and tegafur/gimeracil/oteracil for neoadjuvant treatment of resectable gastric cancer with tumor PD-L1…
On June 8, the Hong Kong Stock Exchange (HKEX) website showed that the IPO application submitted by HighLight Pharmaceutical has been accepted. The joint sponsors for this IPO are CICC and CMB International. Founded in 2017 and headquartered in Hangzhou,…
Nuvalent has been announced to be acquired by GlaxoSmithKline (GSK) on June 9 for $10.6 billion, with an anticipated purchase price of $124 per share, representing a 40% premium over the recent closing price. Nuvalent is a Boston-based clinical-stage biopharmaceutical…
MIL62 (generic name: Obinutuzumab β Injection) has been granted clinical development and commercialization rights in the Asia-Pacific region (including Southeast Asia, India, South Korea, Australia, New Zealand, as well as Hong Kong (China), Macau (China), and Taiwan (China)) under a…
registration, and commercialization in multiple countries and regions across the Asia-Pacific, including Southeast Asia, South Korea, Australia, as well as Hong Kong (China), Macau (China), and Taiwan (China). Vicagrel has been granted exclusive rights for clinical development, registration, and commercialization…